Please assess the completion status of the following clinical trial:

Trial Title: Improving Function,Welfare of Late-stage Cancer Subjects by ACC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Males and females, age \>18 years~2. Signed the informed consent~3. Late Stage Histologically proven advanced solid tumours for which no standard curative therapy exist who failed or refused anti-cancer treatment~4. Subject should not have any illness or condition deemed by the physician to contra-indicate treatment with ACC or may interfere with the assessment of the therapy~5. Performance Status: ECOG 0-3/ Karnofsky performance status \>50~6. Life Expectancy : about 2 months~7. Hormonal therapy is allowed if needed~8. Patient is on conservative treatment for relieving his symptoms~9. Subjects within normal range of serum-corrected albumin calcium (between 7.0-10.5 mg/dl)~10. Acceptable haematology and biochemistry variables:~    WBC ≥3000/mm3 Absolute Neutrophil count ≥ 1500 /mm3 Platelet Count ≥ 100,000/mm3 Hemoglobin ≥ 9 g/dL Bilirubin ≤ 1.5 x ULN ALT and AST ≤ 2.5 x ULN; for patients with hepatic metastases, ALT and AST ≤ 5 x ULN PT/PTT ≤ 1.5 ULN~11. Subjects should have sufficient Vitamin D levels upon study entry, which is defined as 25(OH)D serum level \>20 ng/mL (50 nmol/L) according to a document composed by the Food and Nutrition Board of the Institute of Medicine, USA. If the subject is Vitamin D insufficient or deficient, then a loading dose of Vitamin D3 will be administered during subject's enrollment or during the study as follows:~    1. If the serum 25(OH)D level is 12-20 ng/mL (30-50 nmol/L) then a loading oral dose of 50,000 IU of Vitamin D3 should be administered twice with 3-5 days in between the doses.~   2. If the serum 25(OH)D level is ≤ 12 ng/mL (30 nmol/L), then a loading oral dose of 50,000 IU of Vitamin D3 will be administered three times with 3-5 days in between the doses. Serum 25(OH)D levels will be checked 1-2 weeks following the last loading.~    Nevertheless, if levels of vitamin D levels will not be within the normal range after adjustment efforts, patients will not excluded from the study.~12. Regardless of Vitamin D levels, all subjects will receive a daily maintenance dose of 1000 IU Vitamin D3, which should be taken in the morning with breakfast.~13. Subjects receiving Denosumab or bisphosphonates are eligible. Denosumab or bisphosphonates can be administered during the study to alleviate bone metastasis pain.~14. Negative Pregnancy Test.~Exclusion Criteria:~1. Concurrent treatment with acute anti-cancer therapy~2. Hypercalcemia (serum calcium concentration \> 12.0 mg/dL)~3. Clinical Significant Cardiovascular Disease~4. Known alcohol or drug abuse~5. Any psychiatric condition that would prohibit understanding or rendering of Informed Consent~6. Active Participation in Clinical Trial in the last 2 weeks prior to inclusion~7. Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment.~8. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amorphous calcium carbonate (Type: EXPERIMENTAL): The investigation product will include:~1. ACC tablets, containing 200 mg elemental calcium~2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues